Biocon Biologics Hails ‘Milestone’ Human Insulin Nod

Following EMA CHMP Positive Opinion For Inpremzia Biosimilar In Late February

Biocon Biologics has welcomed the recent “milestone” positive opinion from the EMA’s CHMP for the Inpremzia biosimilar human insulin rival to Actrapid, on which it has partnered with Celerity Pharmaceuticals.

Biocon logo under magnifying glass
Biocon Biologics has partnered with Celerity Pharmaceuticals on Inpremzia • Source: Postmodern Studio / Alamy Stock Photo

India’s Biocon Biologics says the European Medicines Agency’s recent endorsement of the Inpremzia biosimilar fast-acting human insulin rival to Actrapid represents a “milestone” for the company as it continues its efforts to expand access to insulin products.

In late February, the EMA’s committee for medicinal products for human use issued a positive opinion recommending that Inpremzia –...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.